Akebia Therapeutics Inc. Stock
Price
Target price
€3.01
€3.01
-1.180%
-0.036
-1.180%
€6.83
17.06.25 / Stuttgart Stock Exchange
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akebia Therapeutics Inc. Stock
A loss of -1.180% shows a downward development for Akebia Therapeutics Inc..
We see a rather positive sentiment for Akebia Therapeutics Inc. with 12 Buy predictions and 1 Sell predictions.
As a result the target price of 6 € shows a very positive potential of 99.2% compared to the current price of 3.01 € for Akebia Therapeutics Inc..
For the coming years our community has positive and negative things to say abot the Akebia Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -1.180% | -9.609% | 31.153% | 219.497% | 66.466% | 988.183% | -72.037% |
| Krystal Biotech | -1.350% | -6.441% | -3.286% | -31.623% | -25.558% | 113.774% | - |
| Ardelyx Inc. | -1.800% | -5.292% | -10.932% | -47.221% | -37.644% | 490.614% | -47.077% |
| Evolus Inc | -2.370% | -0.588% | -1.744% | -17.157% | -19.524% | -22.477% | 87.778% |
Comments
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat